Vitreous-Retina-Macula Consultants of New York, New York, New York, USA.
Retina. 2011 May;31(5):821-8. doi: 10.1097/IAE.0b013e3181feccc0.
To evaluate long-term effectiveness and safety of intravitreal injection of ranibizumab as a potential treatment for decreased visual acuity secondary to central retinal vein occlusion.
In this prospective interventional case series, patients with central retinal vein occlusion were administered intravitreal ranibizumab 0.5 mg at baseline and monthly for 2 additional doses. Thereafter, the patients were given additional ranibizumab if they had macular edema by optical coherence tomography, leakage during fluorescein angiography, or any intraretinal hemorrhage.
There were 35 eyes of 35 patients who at baseline had a mean visual acuity of 44.2 Early Treatment Diabetic Retinopathy Study letters and a mean central macular thickness of 638 μm. At 12 months, mean visual acuity of 32 eyes improved by 16.5 letters and macular thickness decreased to 164 μm (P < 0.001 vs. baseline for each). At 24 months, mean visual acuity of 24 eyes improved by 17.8 letters and macular thickness was 263 μm (P < 0.001 vs. baseline for each). Patients received an average of 10.2 injections during the first year and 6.6 injections during the second year. No cases of endophthalmitis, retinal detachment, or neovascularization were observed.
Intravitreal ranibizumab caused a significant improvement in visual acuity and central retinal thickness, which persisted for up to 2 years with minimal side effects.
评估玻璃体内注射雷珠单抗治疗视网膜中央静脉阻塞导致的视力下降的长期疗效和安全性。
本前瞻性干预性病例系列研究纳入了视网膜中央静脉阻塞患者，在基线时给予玻璃体内注射雷珠单抗 0.5mg，随后每月追加 2 次，每次 0.5mg。如果光学相干断层扫描显示存在黄斑水肿、荧光素血管造影时存在渗漏或任何视网膜内出血，则给予患者更多的雷珠单抗治疗。
共有 35 例（35 只眼）患者纳入本研究，基线时平均视力为 44.2 个早期治疗糖尿病视网膜病变研究字母，平均黄斑中心厚度为 638μm。治疗 12 个月时，32 只眼的平均视力提高了 16.5 个字母，黄斑厚度降至 164μm（与基线相比，P＜0.001）。治疗 24 个月时，24 只眼的平均视力提高了 17.8 个字母，黄斑厚度为 263μm（与基线相比，P＜0.001）。患者在第一年平均接受了 10.2 次注射，第二年平均接受了 6.6 次注射。未观察到眼内炎、视网膜脱离或新生血管形成的病例。
玻璃体内注射雷珠单抗可显著改善视力和中心视网膜厚度，且疗效可持续长达 2 年，副作用极小。
